Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
NovoCure Logo
NovoCure Growth Score
62
CB Rank
56632
Heat Score
55
An Oncology Company Pioneering a Novel Therapy for Solid Tumors
Founded
obfuscation
PublicPost-IPO Debt Zug, Zug, Switzerland1001-5000 www.novocure.com/
Biotechnology
Health Care
Medical Device
Oncology
Overview

NovoCure
Total Funding
obfuscation
Growth Score
62
Heat Score
55

Total Funding
obfuscation
obfuscation
Post-IPO Debt raised
obfuscation
Growth Score62
-28 pts
in past quarter
Heat Score 55
-28 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About NovoCure

CB Rank
56632
An Oncology Company Pioneering a Novel Therapy for Solid Tumors
Founded
obfuscation
PublicPost-IPO Debt Zug, Zug, Switzerland1001-5000 www.novocure.com/
Biotechnology
Health Care
Medical Device
Oncology

Funding Rounds

Post-IPO Debt
OBF
in
obfuscation
Post-IPO Debt
OBF
in
obfuscation
Post-IPO Debt
OBF
in
obfuscation

Key People

Details

Legal Name Novocure Inc.
Operating Status Active
Stock Symbol  NASDAQ:NVCR
Company Type For Profit
Founders  William F. Doyle, Yoram Palti
About the Company

Novocure™ is dedicated to the development of tumor treating fields therapy (NovoTTF™ Therapy), a new weapon for patients and physicians in the battle against cancer. NovoTTF Therapy is a novel anti-mitotic treatment that has been shown to slow or reverse tumor progression by inducing cell death in certain solid tumors. The company pioneered the

concept that the electric properties of cells can be used as an effective target for an anti-neoplastic therapy.

Phone Number +1 603 436 2809
Contact Email media@novocure.com
Predictions & Insights

Growth Insight

See this Growth Insight
NovoCure is
Lorem
 to be growing
Top Contributing Factors
Financial Growth

Products & Services

Optune
A portable, non-invasive medical device delivering Tumor Treating Fields therapy to disrupt cancer cell division in glioblastoma patients.
NovoTTF-100L System
A device delivering Tumor Treating Fields therapy for malignant pleural mesothelioma in combination with chemotherapy.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 7
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Debt - NovoCure Logo
Post-IPO Debt - NovoCure
1
obfuscation
Pharmakon AdvisorsPost-IPO Debt
obfuscation
Post-IPO Debt - NovoCure Logo
Post-IPO Debt - NovoCure
1
obfuscation
Pharmakon AdvisorsPost-IPO Debt
obfuscation
Post-IPO Debt - NovoCure Logo
Post-IPO Debt - NovoCure
1
obfuscation
Pharmakon AdvisorsPost-IPO Debt
obfuscation
Post-IPO Debt - NovoCure Logo
Post-IPO Debt - NovoCure
1
obfuscation
Pharmakon AdvisorsPost-IPO Debt
obfuscation
Post-IPO Debt - NovoCure Logo
Post-IPO Debt - NovoCure
1
obfuscation
Pharmakon AdvisorsPost-IPO Debt

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 7
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Debt - NovoCure Logo
Post-IPO Debt - NovoCure
1
obfuscation
Pharmakon AdvisorsPost-IPO Debt
obfuscation
Post-IPO Debt - NovoCure Logo
Post-IPO Debt - NovoCure
1
obfuscation
Pharmakon AdvisorsPost-IPO Debt
obfuscation
Post-IPO Debt - NovoCure Logo
Post-IPO Debt - NovoCure
1
obfuscation
Pharmakon AdvisorsPost-IPO Debt
obfuscation
Post-IPO Debt - NovoCure Logo
Post-IPO Debt - NovoCure
1
obfuscation
Pharmakon AdvisorsPost-IPO Debt
obfuscation
Post-IPO Debt - NovoCure Logo
Post-IPO Debt - NovoCure
1
obfuscation
Pharmakon AdvisorsPost-IPO Debt

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Pharmakon Advisors Logo
Pharmakon Advisors
Yes
Post-IPO Debt - NovoCure Logo
Post-IPO Debt - NovoCure
—
Pharmakon Advisors Logo
Pharmakon Advisors
Yes
Post-IPO Debt - NovoCure Logo
Post-IPO Debt - NovoCure
—
Pharmakon Advisors Logo
Pharmakon Advisors
Yes
Post-IPO Debt - NovoCure Logo
Post-IPO Debt - NovoCure
—
Pharmakon Advisors Logo
Pharmakon Advisors
Yes
Post-IPO Debt - NovoCure Logo
Post-IPO Debt - NovoCure
—
Pharmakon Advisors Logo
Pharmakon Advisors
Yes
Post-IPO Debt - NovoCure Logo
Post-IPO Debt - NovoCure
—
Market Intelligence
People
View Profiles & Contacts
Headcount 1001-5000 Employee Profiles 12 Board Members and Advisors 4 Contacts 1,056

Employee Profiles

Board Members and Advisors

News

News and Press

News•May 7, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 5, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 4, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 3, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

31,003
115.6%
 in past month

IT Spend

$35.1MThis year, NovoCure is projected to spend $35.1M on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Trade Spend Optimization Logo
Trade Spend Optimization
100
Intelligent Enterprise Logo
Intelligent Enterprise
98
Decision Engine Logo
Decision Engine
97

Actively Used Products

24NovoCure uses 24 technology products and services including HTML5, GoDaddy Premium DNS, and  Google Tag Manager, according to G2 Stack.

Active Website Tech Count

39NovoCure is actively using 39 technologies for its website, according to BuiltWith. These include DNSSEC, Google Font API, and  IPv6.

Total IP

450The intellectual property of NovoCure includes 384 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery. Additionally, NovoCure has registered 66 trademarks with the most popular class being 'Medical apparatus and instruments', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is NovoCure's headquarters? NovoCure is located in Zug, Zug, Switzerland.Who invested in NovoCure? NovoCure has 8 investors including Pharmakon Advisors and  JP Morgan Chase.When was the last funding round for NovoCure? NovoCure closed its last funding round on
obfuscation
from a Post-IPO Debt round.Who are NovoCure's competitors? Alternatives and possible competitors to NovoCure may include Elbow Beach Capital, Medac, and  Cancer Care Northwest.How much funding has NovoCure raised to date? NovoCure has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(8c8a01a 1)
|